Literature DB >> 12605362

Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features.

Stefano La Rosa1, Silvia Uccella, Giovanna Finzi, Luca Albarello, Fausto Sessa, Carlo Capella.   

Abstract

Angiogenesis, a process related to tumor growth and malignancy, is stimulated by several growth factors. Among these is vascular endothelial growth factor (VEGF), which acts on endothelial cells by binding with 2 specific receptors, VEGFR1 and VEGFR2. Recent studies have demonstrated that VEGF expression is correlated with microvessel density (MVD) and tumor progression. Digestive endocrine tumors are heterogeneous neoplasms exhibiting variable biological aggressiveness and behavior that often are not predictable on morphologic grounds alone. The aims of this study were to evaluate the expression of VEGF, VEGFR1, and VEGFR2 in digestive endocrine tumors and to examine its correlation with MVD and malignancy. A total of 84 specimens from endocrine neoplasms and normal gut and pancreatic tissue were immunohistochemically studied using specific antibodies directed against VEGF, VEGFR1, VEGFR2, endothelial antigens, and gastroenteropancreatic hormones. Ultrastructural immunocytochemistry was performed to identify the cellular localization of VEGF and the VEGFRs. In normal tissues, VEGF immunoreactivity was detected in G cells and PP cells. Ultrastructurally, VEGF was localized within secretory granules. The VEGFRs were not significantly expressed by normal endocrine cells. VEGF-immunoreactive (IR) cells were detected in 40 of 83 tumors, mainly G cell and enterochromaffin cell neoplasms. VEGFR1-IR cells were found in 44 of 82 tumors, and VEGFR2-IR cells were found in 55 of 82 tumors, with no predilection for any specific tumor type. The expression of VEGF and its receptors did not correlate with MVD or malignancy. These results suggest that in normal tissues, endothelial functions may be regulated by VEGF produced by some endocrine cells and that a VEGF/VEGFR binding mechanism may be involved in tumorigenesis, but not in tumor progression and aggressiveness. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605362     DOI: 10.1053/hupa.2003.56

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer.

Authors:  Liwei Wang; Xiaohong Guan; Weida Gong; James Yao; Zhihai Peng; Daoyan Wei; Tsung-Teh Wu; Suyun Huang; Keping Xie
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network.

Authors:  Daniel Menendez; Oliver Krysiak; Alberto Inga; Bianca Krysiak; Michael A Resnick; Gilbert Schönfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

Review 4.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 5.  Targeted therapy in advanced well-differentiated neuroendocrine tumors.

Authors:  Chandrajit P Raut; Matthew H Kulke
Journal:  Oncologist       Date:  2011-02-23

Review 6.  Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.

Authors:  Kein-Leong Yim
Journal:  Endocrine       Date:  2011-08-26       Impact factor: 3.633

Review 7.  Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.

Authors:  Ramon Salazar; Diane Reidy-Lagunes; James Yao
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

8.  A phase II study of axitinib in advanced neuroendocrine tumors.

Authors:  J R Strosberg; M Cives; J Hwang; T Weber; M Nickerson; C E Atreya; A Venook; R K Kelley; T Valone; B Morse; D Coppola; E K Bergsland
Journal:  Endocr Relat Cancer       Date:  2016-04-14       Impact factor: 5.678

9.  Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Wafaey Gomaa; Abdelbaset Buhmeida; Yousif Qari; Mohammad Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Tumour Biol       Date:  2014-06-09

10.  Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.

Authors:  Stefano La Rosa; Silvia Uccella; Linda Dainese; Silvia Marchet; Claudia Placidi; Davide Vigetti; Carlo Capella
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.